ArticleBritish journal of pharmacology2013
Neuroprotective activities of catalpol against CaMKII-dependent apoptosis induced by LPS in PC12 cells.
Article in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Neurotrophic Natural Products.Progress in the chemistry of organic natural products · 2024Article
- Effects of Catalpol on Alzheimer's Disease and Its Mechanisms.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Catalpol Enhances Random-Pattern Skin Flap Survival by Activating SIRT1-Mediated Enhancement of Autophagy.Oxidative medicine and cellular longevity · 2022Article
- A Review of the Pharmacological Properties of Psoralen.Frontiers in pharmacology · 2020Review
- Inhibition of lncRNA Neat1 by catalpol via suppressing transcriptional activity of NF-κB attenuates cardiomyocyte apoptosis.Cell cycle (Georgetown, Tex.) · 2019Article
- The protective effect and mechanism of catalpol on high glucose-induced podocyte injury.BMC complementary and alternative medicine · 2019Article
- Catalpol Ameliorates Podocyte Injury by Stabilizing Cytoskeleton and Enhancing Autophagy in Diabetic Nephropathy.Frontiers in pharmacology · 2019Article
- Targeting Reactive Oxygen Species in Cancer via Chinese Herbal Medicine.Oxidative medicine and cellular longevity · 2019Review
- Enhanced effect of catalpol on specific immune therapy in treatment of asthmatic mice.American journal of translational research · 2019Article
- RhoA/ROCK-2 Pathway Inhibition and Tight Junction Protein Upregulation by Catalpol Suppresses Lipopolysaccaride-Induced Disruption of Blood-Brain Barrier Permeability.Molecules (Basel, Switzerland) · 2018Article
- Catalpol alleviates renal damage by improving lipid metabolism in diabetic db/db mice.American journal of translational research · 2018Article
- Catalpol Inhibits Amyloid-β Generation Through Promoting α-Cleavage of APP in Swedish Mutant APP Overexpressed N2a Cells.Frontiers in aging neuroscience · 2018Article
- RIPK3 interactions with MLKL and CaMKII mediate oligodendrocytes death in the developing brain.Cell death & disease · 2017Article
- A Dual Role of P53 in Regulating Colistin-Induced Autophagy in PC-12 Cells.Frontiers in pharmacology · 2017Article
- Article
- Autophagy regulates colistin-induced apoptosis in PC-12 cells.Antimicrobial agents and chemotherapy · 2015Article
- Gastrodin inhibits glutamate-induced apoptosis of PC12 cells via inhibition of CaMKII/ASK-1/p38 MAPK/p53 signaling cascade.Cellular and molecular neurobiology · 2014Article
- Amelioration of stroke-induced neurological deficiency by lyophilized powder of catapol and puerarin.International journal of biological sciences · 2014Article
- Ceramide mediates Ox-LDL-induced human vascular smooth muscle cell calcification via p38 mitogen-activated protein kinase signaling.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeNeurodegenerative diseases present progressive neurological disorder induced by cell death or apoptosis. Catalpol, an iridoid glucoside isolated from the root of Rehmannia glutinosa Libosch, is present in a wide range of plant families. Although catalpol is an effective anti-apoptotic agent in LPS-induced neurodegeneration, the underlying mechanism has not been established. Here we have identified some of the mechanisms involved the prevention by catalpol of apoptosis induced by LPS in an experimental model of neurodegeneration in vitro. EXPERIMENTAL APPROACH: Apoptosis was induced by adding LPS (80 ng·mL(-1)) to pheochromocytoma (PC12) cells, pretreated with catalpol for 12 h. We measured intracellular reactive oxygen species (ROS), apoptosis and intracellular calcium concentration ([Ca(2+)]i) by flow cytometry or laser confocal scanning microscopy. We also analysed the protein expression of Bcl-2, Bax and Ca(2+)-calmodulin-dependent protein kinase II (CaMKII)-dependent apoptosis signal-regulating kinase-1 (ASK-1)/JNK/p38 signalling pathway in PC12 cells by Western blot. KEY
resultsCatalpol stimulated expression of Bcl-2 and inhibited the expression of Bax. Catalpol also attenuated the increase in Ca(2+) concentration induced by LPS in PC12 cells and down-regulated CaMK phosphorylation. The CaMKII-dependent ASK-1/JNK/p38 signalling cascade was blocked by catalpol. All these changes were accompanied by a decrease of apoptosis induced by LPS in PC12 cells. CONCLUSIONS AND IMPLICATIONS: The data presented here provide new mechanistic insights into the links between the CaMKII-dependent ASK-1/JNK/p38 signalling pathway and the protective effect of catalpol on apoptosis induced by LPS in PC12 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.